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a b s t r a c t
Evidence-based clinical practice guidelines, based on systematic reviews of existing evidence, play an
important role in improving and standardizing the quality of patient care in many medical and psychi-
atric disorders, and could play an important role in the diagnosis and treatment of functional seizures
and other functional neurological disorder (FND) subtypes. There are several reasons to think that
evidence-based guidelines might be especially beneficial for the management of FND. In particular, the
interdisciplinary and multidisciplinary teamwork necessary for the care of people with FND, the current
lack of formal clinical training in FND, and the rapidly expanding body of evidence relating to FND all
make guidelines based on systematic literature reviews especially valuable. In this perspective piece,
we review clinical practice guidelines, their advantages and limitations, the reasons why evidence-
based guidelines might be especially beneficial in the diagnosis and treatment of FND, and the steps that
must be taken to create such guidelines for FND. We propose that professional organizations such as the
American Academy of Neurology and the American Psychiatric Association undertake guideline develop-
ment, ideally to create a co-authored or jointly endorsed set of guidelines that can set standards for inter-
disciplinary care for neurologists and mental health clinicians alike.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
Introduction
Functional seizures and other functional neurological disorder
(FND) subtypes are a common and highly disabling class of condi-
tions. They are thought to be caused by a complex interplay of
biopsychosocial vulnerabilities, often in the setting of psychosocial
and/or physical triggers, and are frequently misdiagnosed as other
neurological disorders [1]. FND is among the most common causes
of neurological disability, diagnosed in approximately 16% of out-
patient neurology consultations, with functional seizures specifi-
cally diagnosed in approximately 25% of epilepsy monitoring unit
admissions [2,3]. FND is associated with reduced quality of life,
decreased employment, and increased dependence on public dis-
ability programs [4,5]. There is a growing body of evidence sug-
gesting that FND may be associated with significantly elevated
healthcare costs, morbidity and rates of mortality [5–8].
There is also growing evidence, including multiple randomized
controlled trials, showing that FND can be effectively treated with
psychotherapy and physiotherapy [9–13]. Single center random-
ized trials of physical therapy for functional movement disorder
have found improved independence and mobility as assessed by
https://doi.org/10.1016/j.ebr.2021.100494
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the Functional Independence Measure, the Functional Mobility
Scale, and by patient self-report [9,10]. For functional seizures,
pilot randomized trials found that the frequency of functional sei-
zures was reduced in participants randomized to receive cognitive
behavioral therapy (CBT) or CBT-informed psychotherapy [11,12].
In addition, the first fully powered multi-center randomized con-
trolled trial of CBT for the treatment of functional seizures was
recently completed demonstrating significant benefits in sec-
ondary outcome measures of psychosocial functioning, psycholog-
ical distress, somatic symptoms, and aspects of seizure control
[14].
While guidelines based on expert consensus regarding the diag-
nosis and treatment of some FND subtypes currently exist, the
growing literature of methodologically rigorous studies now
makes possible the development of evidence-based guidelines for
the management of FND [15–18]. Clinical practice guidelines are
an important tool for standardizing and improving healthcare
practice and offer a unique opportunity to improve diagnostic
and treatment outcomes for patients with FND. In this perspective
piece, we assembled an international, multi-disciplinary group of
clinician researchers in FND to review clinical practice guidelines,
guideline strengths and limitations, reasons why evidence-based
guidelines might be especially beneficial in the diagnosis and treat-
ment of FND, and steps that must be taken to create such guideli-
nes for FND.
What are clinical practice guidelines?
Clinical Practice Guidelines are sets of systematically developed
recommendations to standardize and improve healthcare practice
in specific clinical circumstances [19]. Guidelines attempt to distill
large bodies of information, and historically may draw on clinical
experience, expert opinion, research evidence, or upon an amalga-
mation of these sources of information. Because of the risk of
incomplete and biased data, guidelines based entirely on expert
opinion or consensus or even on a narrative or non-systematic
review of the literature are becoming less acceptable except in cir-
cumstances of limited research evidence [20,21].
Evidence-based guidelines increasingly draw on systematic
reviews of research findings to support clinical recommendations
[22]. Systematic reviews use clearly defined and reproducible liter-
ature search strategies to identify relevant evidence. Such reviews
begin with a carefully defined clinical question, usually identifying
a specific patient population, intervention, comparator (e.g., pla-
cebo, no treatment/test, or alternative treatment/test), and out-
come measure(s) [23]. This clinical question then provides a
framework for defining eligibility criteria for a comprehensive lit-
erature search, using a broad, clearly defined, and reproducible
search strategy in specified databases, such as MEDLINE, Embase,
the Cochrane Library, and EBSCO PsycInfo. Systematic reviews
are ideally reported using the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) [24]. Evidence-
based guidelines grade the amount and quality (or methodological
rigor) of the available evidence before making recommendations.
This helps guideline users to uniformly interpret the degree of cer-
tainty underlying specific recommendations. Grading of evidence
is increasingly done using established rubrics, such as the GRADE
(Grading of Recommendations, Assessment, Development, and
Evaluation) system, and the National Academy of Medicine’s (for-
merly the Institute of Medicine’s) overlapping criteria for trustwor-
thy guidelines [21,25]. Judgements about the quality of evidence
made using the GRADE system have good inter-rater reliability
when compared with intuitive judgements [26]. While expert
judgement may supplement research evidence, high quality
evidence-based guidelines now explicitly and transparently iden-
tify exactly when and where such expert opinion plays a role in
guideline development [23]. Ultimately, guidelines use the number
and methodology classification (I-IV) of individual studies to deter-
mine an overall level of evidence for each conclusion, with
evidence-based conclusions then serving as the basis for practice
recommendations.
In the United States (US), large professional organizations such
as the American Medical Association, the American Academy of
Neurology, and the American Psychiatric Association are among
the most prolific developers of clinical practice guidelines, along
with government panels and cooperative groups. The National
Guideline Clearing House, run by the US Agency for Healthcare
Research and Quality, is a register of clinical practice guidelines
that meet minimal quality criteria, though it is now threatened
by lack of federal funding [27]. The primary audience for clinical
practice guidelines are clinicians and patients making decisions
about healthcare in specific clinical circumstances. Guidelines are
also widely used by healthcare systems, policy makers, and insur-
ers to measure quality of care, allocate healthcare resources, and
determine insurance coverage. Guidelines also play an important
role for healthcare systems as references for quality assurance
and improvement efforts, and for researchers and funding organi-
zations in identifying gaps in knowledge where future research is
needed.
Advantages and limitations of evidence-based guidelines
There is a large and growing research literature showing that
adherence to evidence-based guidelines lowers mortality rates
and healthcare costs in disorders including breast cancer [28],
ovarian cancer [29], pneumonia [30], heart failure [31], coronary
artery disease [32], and atrial fibrillation [33]. Similarly, studies
demonstrate that adherence to evidence-based guidelines results
in greater symptom reduction in major depressive disorder [34],
reduced medication adverse effects and greater symptom reduc-
tion in schizophrenia [35,36], lower healthcare costs in lower-
back pain [37], and greater likelihood of achieving blood glucose
control in diabetes [38]. In surveys, the majority of physicians
endorse a need for evidence-based guidelines and believe that they
improve patient care [39–41]. Indirect benefits of clinical practice
guidelines are widely hypothesized but not yet formally studied
[20,27,42]. These include directing healthcare resources toward
evidence-based interventions and directing research attention
and funding toward gaps in clinical knowledge.
On the other hand, historically, some physicians have raised
concerns that guidelines might enforce overly rigid or ‘‘cookie-
cutter” healthcare practices that fail to make allowances for indi-
vidual needs, or that guidelines might increase legal liability for
physicians who deviate from the guidelines or for professional
organizations that publish or endorse guidelines. Surveys of physi-
cians who have used clinical practice guidelines over the past 4
decades have not found these problems to be significantly borne
out in practice [39–41]. However, some important limitations have
become apparent with the ongoing development and use of
guidelines.
Because guidelines require multidisciplinary groups of experts
to collect and assess evidence and to generate recommendations,
and because many clinical and research experts in the US collabo-
rate with industry or for-profit healthcare corporations, there is a
potential for real and perceived conflicts of interest [43]. This risk
can be reduced through the implementation of the National Acad-
emy of Medicine’s mandates for conflict of interest disclosure and
voting and authorship restrictions among guideline developers
[21]. Another limitation of guidelines is the proliferation of some-
times redundant guidelines, which can leave clinicians and
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patients overwhelmed and confused. This issue can be mitigated
through the use of a single publicly accessible and searchable cen-
tral repository for evidence-based guidelines, such as the National
Guidelines Clearinghouse. A third limitation is that guidelines
rapidly become outdated as new evidence accumulates, with 1 in
5 recommendations becoming outdated within 3 years [44]. As a
result, mechanisms (including the pre-requisite funding) for peri-
odic updating of published guidelines are required. Finally, guide-
lines have only an indirect and delayed effect on clinical practice,
and require large scale education, decision aids, and other imple-
mentation science interventions in order to achieve maximal
impact [45]. Monitoring adherence to guidelines is essential to
understand positive and negative clinical impacts of their use.
The potential role of clinical practice guidelines in functional
neurological disorder
Abundant evidence exists showing that adherence to clinical
practice guidelines improves patient care and outcomes in a broad
range of medical, neurological, and psychiatric disorders. There is
little reason to think that patients with FND could not also benefit
from evidence-based guidelines, as the evidence-base in FND con-
tinues to grow. Moreover, there are several specific factors that
might make guidelines particularly beneficial in the field of FND.
These factors include the need for interdisciplinary and multidisci-
plinary teams in the evaluation and treatment of FND, clinicians’
current lack of training in FND, and the relatively new and rapidly
expanding research literature pertaining to FND.
FND, to an even greater extent than many other neuropsychi-
atric disorders, require a multidisciplinary team for effective diag-
nosis and treatment. Neurologists most often have the training and
experience to diagnose (rule-in) FND and to differentiate them
from other neurological disorders such as epilepsy, dystonia, and
stroke with which FND are frequently misdiagnosed [1]. At the
same time, mental health clinicians (psychiatrists, clinical
psychologists/neuropsychologists, and psychotherapists), and
rehabilitation specialists (physiatrists and physical, occupational,
and speech therapists) most often have the requisite training and
experience to provide evidence-based psychotherapeutic and reha-
bilitative treatment regimens [14]. Very few clinicians have the
requisite training in both neurodiagnostics and psychotherapeutics
to confidently and successfully diagnose and treat functional neu-
rological disorders, in the absence of a multidisciplinary team.
As a result, clinicians involved in the evaluation and treatment
of FND necessarily rely on clinical judgments, which they them-
selves may not have sufficient expertise to evaluate. For example,
the majority of mental health specialists expressed doubt regard-
ing diagnosis of functional seizures via video-
electroencephalogram, when in fact this is the gold standard for
the diagnosis of the disorder [15,46]. Similarly, many neurologists
and emergency medicine clinicians are unfamiliar with the treat-
ment of FND, and incorrectly regard patients with FND as ‘‘faking”
their symptoms, rather than as experiencing a disabling disorder
that is amenable to psychotherapeutic and rehabilitative treatment
[47]. These clinicians often leave patients newly diagnosed with an
FND with little guidance beyond the negative judgment that they
do not have a neurological disorder such as epilepsy or a move-
ment disorder, and a vague recommendation to seek evaluation
from a mental health specialist. Guidelines – particularly guideli-
nes endorsed by both neurological and psychiatric professional
associations -- may therefore be helpful in establishing a shared
understanding of FND across multiple clinical specialties as a seri-
ous and disabling neuropsychiatric disorder, in which best prac-
tices in diagnosis and treatment can bring real and meaningful
improvements in patients’ symptoms, function and quality of life.
Such shared understanding of best practices provides a foundation
for necessary interdisciplinary collaboration, even among clini-
cians who do not have a pre-existing working relationship.
Beyond providing a necessary foundation for attitudinal
changes and multidisciplinary collaboration among clinicians,
evidence-based guidelines also can form a basis for supportive
social changes, including reimbursement of clinicians and hospi-
tals by public and private health insurance agencies, and social ser-
vices support for patients and their caretakers. Reliable
reimbursement of clinical care and social services support are nec-
essary prerequisites to making treatment available and accessible
to patients on a societal scale, beyond the efforts of specialty aca-
demic medical centers and research programs.
Another current challenge in the care of patients with func-
tional seizures or other FND subtypes is the relative lack of formal
clinical training relating to FND. The majority of mental health spe-
cialists report receiving little or no training in the management of
FND [48]. Similarly, most neurologists and internists report impor-
tant gaps in their training related to FND [49] (see also Milligan
et al. Neurology Residents Education in Functional Seizures. Else-
where in this issue). Evidence-based guidelines provide an objec-
tive framework around which to structure clinical education and
facilitate curricular development. Evidence-based guidelines also
provide the foundation for the development of standardized board
examination questions and the educational milestones promul-
gated by the Accreditation Council for Graduate Medical Education
(ACGME) [50]. Board examinations and ACGME milestones collec-
tively set national standards for resident training in neurology,
psychiatry, and other medical specialties.
Finally, the field of FND research is currently undergoing a per-
iod of exponential growth [1]. While this is bringing important
advances in diagnosis and treatment, it also creates challenges
for busy clinicians seeking to provide patients with guidance and
recommendations, and for researchers seeking to build on prior
studies. Evidence-based guidelines built on systematic reviews
provide clinicians with unified and easily digestible summaries of
the existing evidence and the resulting practice implications [20].
Similarly, systematic reviews and guidelines provide researchers
and funders with clear maps of the existing literature, and of key
lacunae as topics for future research.
Necessary steps to create evidence-based guidelines for
functional neurological disorder
Clinical practice guidelines and reviews, based on expert con-
sensus and narrative reviews of the literature, currently exist for
the management of functional seizures and functional movement
disorders – the most common forms of FND [15–18,51–53]. While
these guidelines have raised awareness around FND, they have
thus far failed to create a widely shared standard of clinical prac-
tice [47]. The few existing evidence-based guidelines have thus
far been unable to muster sufficient evidence to support clinical
recommendations [54]. Historically, professional organizations
such as the American Academy of Neurology and the American
Psychiatric Association have been reluctant to undertake the devel-
opment of evidence-based guidelines because of the lack of fully
powered randomized trials. This is because a minimum of at least
one high quality randomized controlled trial is often (although not
always) required to generate even the lowest level of evidence-
based recommendations under the GRADE system and the grading
variants used by professional organizations such as the American
Academy of Neurology [23]. In the absence of such studies,
evidence-based guidelines could be developed but would not sup-
port any evidence-based recommendations beyond recommenda-
tions for further study.
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In June 2020, the CODES study group in the United Kingdom
published their large multicenter trial of cognitive behavioral ther-
apy for the treatment of functional seizures. Despite not showing a
statistically significant beneficial effect of adding their model of
cognitive behavioral therapy to standardized medical care in
reducing seizure occurrence at 12 months post randomization,
the study demonstrated effectiveness of the cognitive behavioral
therapy intervention in improving length of time without seizures,
aspects of quality of life, psychosocial functioning, psychological
distress, and somatic symptoms [14]. Smaller randomized trials
of other psychotherapies and observational treatment studies have
shown reduction in seizures/movements, improvements in comor-
bidities, quality of life, and functioning, and in combination with
the CODES trial results, the studies offer the possibility of the first
evidence-based recommendations in the management of FND [11–
13]. While the systematic collection and synthesis of evidence, the
development of recommendations, and the authoring and approval
of the written guidelines typically takes multiple years, this pro-
cess can now begin. Because FND are managed by multidisci-
plinary teams, the guideline development process will ideally
involve multiple professional organizations representing neurolog-
ical, mental health, and rehabilitation clinicians either co-
authoring or jointly endorsing a single set of recommendations.
Such a guideline has been proposed within the American Academy
of Neurology as an initial step.
Of note, existing randomized trials have focused on specific
treatment modalities and specific subtypes of FND, such as CBT
for functional seizures, or specialist physical therapy in an inten-
sive outpatient (day program) setting [9,14]. Given the broad range
of treatment modalities, symptom heterogeneity in FND, and the
multiple etiological factors and mechanisms, additional random-
ized trials focusing on other treatment targets that combine exper-
tise from different disciplines are needed to broaden the existing
evidence base (see Fobian and Szaflarski. Identifying and evaluat-
ing novel treatment targets for the development of evidence-
based interventions for functional neurological disorder. Elsewhere
in this issue). In the short term, initial evidence-based clinical prac-
tice guidelines may be relatively narrowly tailored given the lim-
ited scope of existing studies. The development of useful clinical
practice guidelines over the coming years, and the expansion of
these guidelines as new studies are completed, will require the
concerted efforts of an expert multidisciplinary task force.
Conclusions
Evidence-based guidelines provide important benefits in terms
of improving and standardizing quality of care, and there are sev-
eral reasons to think that they might provide particular benefit in
improving the management of FND. In particular, the multidisci-
plinary teamwork necessary for the care of people with FND, the
current lack of formal clinical training in FND, and the rapidly
expanding body of evidence relating to FND all make guidelines
based on systematic literature reviews especially valuable.
Recently published randomized clinical trials make possible
evidence-based recommendations for FND under formal systems
for evaluating evidence such as the GRADE system and the
National Academy of Medicine’s criteria for trustworthy guide-
lines. Next steps will require professional organizations such as
the American Academy of Neurology and the American Psychiatric
Association to undertake guideline development, ideally to create a
co-authored or jointly endorsed set of guidelines that can set stan-
dards for care for neurologists and mental health clinicians alike.
Through collaboration with global organizations such as England
and Wales’ National Institute for Health and Care Excellence, the
Scottish Intercollegiate Guidelines Network, and the international
Functional Neurological Disorder Society, we can begin to establish
unified global standards for the management of FND.
Ethical statement
This opinion piece does not constitute human research and does
not involve patients, research volunteers, or consent procedures.
Disclosures
Benjamin Tolchin has received research funding from a US
Veteran Administration (VA)’s VISN1 Career Development Award,
the VA Pain Research, Informatics, Multimorbidities, and Education
(PRIME) Center of Innovation, and the C.G. Swebilius Trust. He has
received honoraria from Columbia University Medical Center, the
International League against Epilepsy, and the American Academy
of Neurology.
Gaston Baslet has received honoraria for continuing medical
education lectures on functional neurological disorder and roy-
alties from Oxford University Press.
Alan Carson is a paid editor of the Journal of Neurology, Neuro-
surgery, and Psychiatry, and the unpaid president-elect of the
Functional Neurological Disorders Society.
Barbara A. Dworetzky is on the board of directors of the Amer-
ican Epilepsy Society and the professional advisory board for the
Epilepsy Foundation of New England. She receives salary support
from the A. J. Trustey Research Fund, royalties from Oxford Univer-
sity Press, consultant fees from Bioserenity and Best Doctors. She is
on the editorial board of nonepilepticseizures.com and has
received honoraria for continuing medical education lectures on
FND from Oakstone publishing.
Laura H. Goldstein receives is a Director of the FND Society and
a member of the Medical Advisory Board for FND Action. She
receives royalties from Wiley and from Taylor & Francis and salary
support from the National Institute for Health Research (NIHR)
Maudsley Biomedical Research Centre at the South London and
Maudsley NHS Foundation Trust and King’s College London. The
views expressed in this publication are those of the author and
not necessarily those of the NHS, the NIHR or the Department of
Health and Social Care.
W. Curt LaFrance, Jr. has served on the editorial boards of
Epilepsia, Epilepsy & Behavior; Journal of Neurology, Neurosurgery
and Psychiatry, and Journal of Neuropsychiatry and Clinical Neuro-
sciences; receives editor’s royalties from the publication of Gates
and Rowan’s Nonepileptic Seizures, 3rd ed. (Cambridge University
Press, 2010) and 4th ed. (2018); author’s royalties for Taking Con-
trol of Your Seizures: Workbook and Therapist Guide (Oxford
University Press, 2015); has received research support from the
Department of Defense (DoD W81XWH-17–0169), NIH (NINDS
5K23NS45902 [PI]), Providence VAMC, Center for Neurorestoration
and Neurotechnology, Rhode Island Hospital, the American Epi-
lepsy Society (AES), the Epilepsy Foundation (EF), Brown University
and the Siravo Foundation; serves on the Epilepsy Foundation New
England Professional Advisory Board, the Functional Neurological
Disorder Society Board of Directors, the American Neuropsychiatric
Association Advisory Council; has received honoraria for the AES
Annual Meeting; has served as a clinic development consultant
at University of Colorado Denver, Cleveland Clinic, Spectrum
Health, Emory University, Oregon Health Sciences University and
Vanderbilt University; and has provided medico- legal expert
testimony.
Steve Martino reports no competing interests.
David L. Perez has received honoraria for continuing medical
education lectures on functional neurological disorder and is on
the editorial board of Epilepsy & Behavior.
B. Tolchin, G. Baslet, A. Carson et al. Epilepsy & Behavior Reports 16 (2021) 100494
4
Markus Reuber receives a salary from Elsevier as Editor-in-Chief
of Seizure – European Journal of Epilepsy. He receives royalties
from Oxford University Press for a number of books including
books on FND. MR is on the board of the FND society and the med-
ical advisory board of FND action and FND hope. In the last
24 months he has received speaker’s fees and educational grants
from UCB Pharma, Eisai and Livanova.
Jon Stone receives royalties from UpToDate for articles on FND
and has received honoraria for continuing medical education lec-
tures on FND. He runs a free self-help website for people with
FND at neurosymptoms.org. JS carries out independent expert
medicolegal work including in relation to FND. JS is secretary of
the FND society and on the medical advisory board for FND Hope
and FND Action. He has received funding from Scottish Govern-
ment and the National Institute of Health Research.
Jerzy P. Szaflarski – In the last 24 months, Dr. Szaflarski received
funding from the National Institutes of Health, National Science
Foundation, Shor Foundation for Epilepsy Research, Department
of Defense, UCB Pharma Inc., NeuroPace Inc., Greenwich Bio-
sciences Inc., Biogen Inc., Xenon Pharmaceuticals, Serina Therapeu-
tics Inc., and Eisai, Inc.; has served on consulting and advisory
boards for Greenwich Biosciences Inc., NeuroPace, Inc., Medical
Association of the State of AL, Serina Therapeutics Inc., LivaNova
Inc., UCB Pharma Inc., Lundbeck, SK LifeSciences, Alabama State
Medical Cannabis Study Commission, National Coordinating Center
for Epilepsy under the Health Resources and Services Administra-
tion (HRSA)/Maternal and Child Health Bureau (MCHB), and Elite
Medical Experts LLC; and on editorial boards for Epilepsy & Behav-
ior, Journal of Epileptology (associate editor), Epilepsy & Behavior
Reports (associate editor), Journal of Medical Science, Epilepsy Cur-
rents (contributing editor), and Folia Medica Copernicana.
References
[1] Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett M, et al. Current
concepts in diagnosis and treatment of functional neurological disorders. JAMA
Neurol 2018;75(9):1132. https://doi.org/10.1001/jamaneurol.2018.1264.
[2] Stone J, Carson A, Duncan R, Roberts R, Warlow C, Hibberd C, et al. Who is
referred to neurology clinics?—the diagnoses made in 3781 new patients. Clin
Neurol Neurosurg 2010;112(9):747–51.
[3] Salinsky M, Spencer D, Boudreau E, Ferguson F. Psychogenic nonepileptic
seizures in US veterans. Neurology 2011;77(10):945–50.
[4] Jones B, Reuber M, Norman P. Correlates of health-related quality of life in
adults with psychogenic nonepileptic seizures: A systematic review. Epilepsia
2016;57(2):171–81.
[5] Jennum P, Ibsen R, Kjellberg J. Welfare consequences for people diagnosed
with nonepileptic seizures: A matched nationwide study in Denmark. Epilepsy
Behav 2019;98(Pt A):59–65.
[6] Nightscales R, McCartney L, Auvrez C, Tao G, Barnard S, Malpas CB, et al.
Mortality in patients with psychogenic nonepileptic seizures. Neurology
2020;95(6):e643–52.
[7] Duncan R, Oto M, Wainman-Lefley J. Mortality in a cohort of patients with
psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry 2012;83
(7):761–2.
[8] Stephen CD, Fung V, Lungu CI, Espay AJ. Assessment of Emergency Department
and Inpatient Use and Costs in Adult and Pediatric Functional Neurological
Disorders. JAMA Neurology 2021;78(1):88–101.
[9] Nielsen G, Buszewicz M, Stevenson F, Hunter R, Holt K, Dudziec M, et al.
Randomised feasibility study of physiotherapy for patients with functional
motor symptoms. J Neurol Neurosurg Psychiatry 2017;88(6):484–90.
[10] Jordbru A, Smedstad L, KlungsÃyr O, Martinsen E. Psychogenic gait disorder: a
randomized controlled trial of physical rehabilitation with one-year follow-up.
J Rehabil Med 2014;46(2):181–7.
[11] Goldstein LH, Chalder T, Chigwedere C, Khondoker MR, Moriarty J, Toone BK,
et al. Cognitive-behavioral therapy for psychogenic nonepileptic seizures: a
pilot RCT. Neurology 2010;74(24):1986–94.
[12] LaFrance WC, Baird GL, Barry JJ, Blum AS, Frank Webb A, Keitner GI, et al.
Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a
randomized clinical trial. JAMA Psychiatry 2014;71(9):997. https://doi.org/
10.1001/jamapsychiatry.2014.817.
[13] Sharpe M, Walker J, Williams C, Stone J, Cavanagh J, Murray G, et al. Guided
self-help for functional (psychogenic) symptoms: a randomized controlled
efficacy trial. Neurology 2011;77(6):564–72.
[14] Goldstein LH, Robinson EJ, Mellers JDC, Stone J, Carson A, Reuber M, et al.
Cognitive behavioural therapy for adults with dissociative seizures (CODES): a
pragmatic, multicentre, randomised controlled trial. The Lancet Psychiatry
2020;7(6):491–505.
[15] LaFrance WC, Baker GA, Duncan R, Goldstein LH, Reuber M. Minimum
requirements for the diagnosis of psychogenic nonepileptic seizures: a
staged approach: a report from the International League Against Epilepsy
Nonepileptic Seizures Task Force. Epilepsia 2013;54(11):2005–18.
[16] LaFrance Jr WC, Reuber M, Goldstein LH. Management of psychogenic
nonepileptic seizures. Epilepsia 2013;54(Suppl 1):53–67.
[17] Baslet G, Bajestan SN, Aybek S, Modirrousta M, D.Clin.Psy JP, Cavanna A, et al.
Evidence-based practice for the clinical assessment of psychogenic
nonepileptic seizures: A report from the American Neuropsychiatric
Association Committee on Research. J Neuropsychiatry Clin Neurosci
2021;33(1):27–42.
[18] Perez DL, Aybek S, Popkirov S, Kozlowska K, Stephen CD, Anderson J, et al. A
review and expert opinion on the neuropsychiatric assessment of motor
functional neurological disorders. J Neuropsych Clin Neurosci 2021;33
(1):14–26.
[19] Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation between
systematic reviews and practice guidelines. Ann Intern Med 1997;127
(3):210–6.
[20] Lim W, Arnold DM, Bachanova V, Haspel RL, Rosovsky RP, Shustov AR, et al.
Evidence-based guidelines—an introduction. ASH Education Program Book.
2008;2008(1):26-30.
[21] Steinberg E, Greenfield S, Wolman DM, Mancher M, Graham R. Clinical practice
guidelines we can trust. National Academies Press; 2011.
[22] Lunny C, Ramasubbu C, Gerrish S, Liu T, Salzwedel DM, Puil L, et al. Impact and
use of reviews and ‘overviews of reviews’ to inform clinical practice guideline
recommendations: protocol for a methods study. BMJ Open 2020;10(1):
e031442. https://doi.org/10.1136/bmjopen-2019-031442.
[23] Gronseth GS, Cox J, Gloss D, Merillat S, Dittman J, Armstrong MJ, et al. AAN
clinical practice guideline process manual. St Paul: American Academy of
Neurology; 2017.
[24] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
The PRISMA 2020 statement: an updated guideline for reporting systematic
reviews. BMJ 2021;372:n71.
[25] Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:
1. Introduction—GRADE evidence profiles and summary of findings tables. J
Clin Epidemiol 2011;64(4):383–94.
[26] Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The
GRADE approach is reproducible in assessing the quality of evidence of
quantitative evidence syntheses. J Clin Epidemiol 2013;66(7):736–742.e5.
[27] Shekelle PG. Clinical practice guidelines: What’s Next? JAMA 2018;320
(8):757–8.
[28] Ricci-Cabello I, Vásquez-Mejía A, Canelo-Aybar C, Niño de Guzman E, Pérez-
Bracchiglione J, Rabassa M, et al. Adherence to breast cancer guidelines is
associated with better survival outcomes: a systematic review and meta-
analysis of observational studies in EU countries. BMC Health Serv Res
2020;20(1). https://doi.org/10.1186/s12913-020-05753-x.
[29] Lee J-Y, Kim TH, Suh DH, Kim JW, Kim HS, Chung HH, et al. Impact of guideline
adherence on patient outcomes in early-stage epithelial ovarian cancer. Eur J
Surg Oncol (EJSO) 2015;41(4):585–91.
[30] Wilke M, Grube R, Bodmann K. Guideline-adherent initial intravenous
antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is
clinically superior, saves lives and is cheaper than non guideline adherent
therapy. Eur J Med Res 2011;16(7):315–23.
[31] Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ,
Erdmann E, et al. Adherence to guidelines is a predictor of outcome in chronic
heart failure: the MAHLER survey. Eur Heart J 2005;26(16):1653–9.
[32] Ancedy Y, Lecoq C, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, et al.
Antithrombotic management in patients with atrial fibrillation undergoing
coronary stent implantation: what is the impact of guideline adherence? Int J
Cardiol 2016;203:987–94.
[33] Proietti M, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GYH.
Adherence to antithrombotic therapy guidelines improves mortality among
elderly patients with atrial fibrillation: insights from the REPOSI study. Clin
Res Cardiol 2016;105(11):912–20.
[34] Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al.
Clinical results for patients with major depressive disorder in thetexas
medication algorithm project. Arch Gen Psychiatry 2004;61(7):669. https://
doi.org/10.1001/archpsyc.61.7.669.
[35] Weinmann S, Hoerger S, Erath M, Kilian R, Gaebel W, Becker T. Implementation
of a schizophrenia practice guideline: clinical results. J Clin Psychiat 2008;69
(8):1299–306.
[36] Miller AL, Crismon ML, Rush AJ, Chiles J, Kashner TM, Toprac M, et al. The Texas
medication algorithm project: clinical results for schizophrenia. Schizophr Bull
2004;30(3):627–47.
[37] Hanney WJ, Masaracchio M, Liu X, Kolber MJ, Thompson Coon Jo. The
influence of physical therapy guideline adherence on healthcare utilization
and costs among patients with low back pain: a systematic review of the
literature. PLoS ONE 2016;11(6):e0156799. https://doi.org/10.1371/journal.
pone.0156799.
[38] Lian J, Liang Y. Diabetes management in the real world and the impact of
adherence to guideline recommendations. Curr Med Res Opin 2014;30
(11):2233–40.
[39] Siriwardena AN. Clinical guidelines in primary care: a survey of general
practitioners’ attitudes and behaviour. Br J Gen Pract 1995;45(401):643–7.
B. Tolchin, G. Baslet, A. Carson et al. Epilepsy & Behavior Reports 16 (2021) 100494
5
[40] Alexander PE, Li S-A, Tonelli M, Guyatt G. Canadian primary care Physicians’
Attitudes toward understanding clinical Practice guidelines for Diabetes
Screening. Can J Diabetes 2016;40(6):580–5.
[41] Lunyera J, Jonassaint C, Jonassaint J, Shah N. Attitudes of primary care
physicians toward sickle cell disease care, guidelines, and comanaging
hydroxyurea with a specialist. J Prim Care Community Health 2017;8
(1):37–40.
[42] Murad MH. Clinical Practice Guidelines: A Primer on Development and
Dissemination. Mayo Clin Proc 2017;92(3):423–33.
[43] Sox HC. Conflict of interest in practice guidelines panels. JAMA 2017;317
(17):1739–40.
[44] García LM, Sanabria AJ, Álvarez EG, Trujillo-Martín MM, Etxeandia-Ikobaltzeta
I, Kotzeva A, et al. The validity of recommendations from clinical guidelines: a
survival analysis. CMAJ 2014;186(16):1211–9.
[45] Lugtenberg M, Burgers JS, Han D, Westert GP. General practitioners’
preferences for interventions to improve guideline adherence. J Eval Clin
Pract 2014;20(6):820–6.
[46] Harden CL, Burgut FT, Kanner AM. The diagnostic significance of video-EEG
monitoring findings on pseudoseizure patients differs between neurologists
and psychiatrists. Epilepsia 2003;44(3):453–6.
[47] Tolchin B, Martino S, Hirsch LJ. Treatment of patients with psychogenic
nonepileptic attacks. JAMA 2019;321(20):1967. https://doi.org/
10.1001/jama.2019.3520.
[48] Aatti Y, Schwan R, Maillard L, McGonigal A, Micoulaud-Franchi J-A, de Toffol B,
et al. A cross-sectional survey on French psychiatrists’ knowledge and
perceptions of psychogenic nonepileptic seizures. Epilepsy Behav
2016;60:21–6.
[49] Lehn A, Bullock-Saxton J, Newcombe P, Carson A, Stone J. Survey of the
perceptions of health practitioners regarding Functional Neurological
Disorders in Australia. J Clin Neurosci 2019;67:114–23.
[50] The neurology milestone project. J Grad Med Educ. 2014;6(1 Suppl 1):105-15.
[51] Nielsen G, Stone J, Matthews A, Brown M, Sparkes C, Farmer R, et al.
Physiotherapy for functional motor disorders: a consensus recommendation. J
Neurol Neurosurg Psychiatry 2015;86(10):1113–9.
[52] Nicholson C, Edwards MJ, Carson AJ, Gardiner P, Golder D, Hayward K, et al.
Occupational therapy consensus recommendations for functional neurological
disorder. J Neurol Neurosurg Psychiatry 2020;91(10):1037–45.
[53] Baker J, Barnett C, Cavalli L, Dietrich M, Dixon L, Duffy JR, et al. Management of
functional communication, swallowing, cough and related disorders:
consensus recommendations for speech and language therapy. J Neurol
Neurosurg Psychiatry 2021;92(10):1112–25.
[54] Martlew J, Pulman J, Marson AG. Psychological and behavioural treatments for
adults with non-epileptic attack disorder. Cochrane Database Syst Rev 2014
(2). Cd006370.
B. Tolchin, G. Baslet, A. Carson et al. Epilepsy & Behavior Reports 16 (2021) 100494
6
